Torrent Pharma Results

Torrent Pharmaceuticals on Tuesday reported a 3.3 per cent increase in consolidated net profit at Rs 566 crore in the first quarter ended June 30, 2026. The company had posted a consolidated net profit of Rs 548 crore in the corresponding quarter last fiscal, Torrent Pharmaceuticals Ltd said in a regulatory filing. Consolidated total revenue from operations in the first quarter stood at Rs 4,921 crore as against Rs 3,178 crore in the year-ago period, it added. Total expenses in the quarter under review were higher at Rs 4,155 crore as compared to Rs 2,403 crore in the same quarter a year ago, the company said. India revenues were at Rs 2,157 crore in the first quarter, up 19 per cent from the year-ago period, and US revenues were also at Rs 418 crore, up 36 per cent, it added. Brazil revenues stood at Rs 277 crore, up 27 per cent, and the same for Germany was at Rs 318 crore, up 3 per cent year-on-year, the company said.

Torrent Pharma reported a 26.2 per cent jump in its net profit to ₹635 crore in Q3FY26. On a sequential basis, profit increased 7.4 per cent from ₹591 crore

Ahmedabad-based drugmaker reports Rs 635 crore Q3 profit on strong India, Brazil and US growth; revenues rise 17.6% to Rs 3,303 crore

Torrent Pharma Q3 revenue from operations increased 17.7 per cent year-on-year (Y-o-Y) to ₹3,251 crore from ₹2,762 crore in Q3FY25

Torrent's chronic business grew at 13 per cent as compared to the Indian pharmaceutical market's (IPM) growth of 9 per cent for the quarter.

Torrent Pharma share price rose after JPMorgan reportedly upgraded the company to 'Overweight'. The brokerage also hiked the target price to ₹3,800, from ₹3,650 earlier.

Torrent Pharma posts Rs 498 crore PAT in Q4FY25; Aman Mehta to become MD from August 1 as part of long-term strategic succession planning by the board

Led by an 18% y-o-y growth in the domestic formulations segment, which accounts for over half its overall revenues, the company posted 16% growth at a consolidated level

The company exhibited a 2.66 per cent increase in revenue and was able to turn around the PAT by 2.09 per cent

Brazil revenues for the quarter came in at Rs 185 crore, up by 19 percent. US revenues for the quarter were Rs 292 crore, up by 3 percent. Germany revenue was down 12 percent to Rs 220 crore

First major acquisition by Aman Mehta after taking charge at Torrent Pharma in August

Drug firm Torrent Pharma reported a 3.18 per cent rise in its consolidated net profit to Rs 324 crore for the quarter ended March 31, 2021

India revenues grew 7% to stand at Rs 930 cr. Company's consolidated total revenue from operations fell marginally by under 1% to Rs 2,003 cr in Q3FY21

The firm reported an 18.32 per cent rise in its consolidated net profit to Rs 297 crore for the quarter ended in December.

Domestic and US market revenues more or less flat, 20% drop in Brazilian revenues

The company saw its total consolidated revenue in Q4FY20 at Rs 1961 crore, up by a marginal 4.69 per cent over Rs 1873 crore in Q4FY19

US business down by 22% in third quarter, India revenues grow by 5%

The company had witnessed a PBT of Rs 501.87 crore in the corresponding quarter last year on a consolidated basis

Ahmedabad based Pharmaceuticals major, Torrent Pharmaceuticals Limited has posted a 35 per cent year on year (YoY) dip in net profit for the quarter ended June 30, 2017 as its revenues too dipped by 11.4 per centFor the first quarter of the current fiscal, Torrent Pharmaceuticals posted revenues of Rs 1374 crore as against Rs. 1,551 crores during the same period last year. EBIDTA for Q1FY18 was at Rs. 400 crore as against Rs. 462 crore during the same period last year. Profit after tax (PAT) for Q1FY18 was at Rs. 188 crore as against Rs.292 crore during the same period last year. The company said that the previous period include exceptional revenues and profits which was primarily on account of the launch of a new product in US market, which had limited competition. Research and development (R&D) spend during the Q1 FY 2017-18 was Rs 101 crore as against Rs 90 crore during the same period last year. The domestic formulation business recorded revenues of Rs. 464 crore for .